The Coming Age of Personal Genetic Medicine
December 18, 2025 · Frisian News
Gene sequencing costs have fallen from millions to hundreds of dollars, pushing hospitals and clinics worldwide to adopt personalized treatment plans based on individual DNA. The shift promises better outcomes but raises tough questions about who pays, who has access, and who controls the data.
A 54-year-old woman in Copenhagen walked into her cancer clinic last spring with her personal genome report in hand. Her tumor DNA showed a mutation that made it vulnerable to a drug she had never heard of, one that standard treatment protocols would never have prescribed. She started the new drug, and six months later, her scans came back clear. That case repeats itself thousands of times each month now, across hospitals in Europe, Asia, and North America. The cost of full genome sequencing has crashed from $3 million in 2003 to under $200 today, and that fall shows no sign of stopping.
Hospitals race to build genetic labs and hire specialists to read the data. Insurance companies struggle to decide which tests they will cover. Pharmaceutical firms retrain their entire sales teams because drugs no longer fit neat categories. A cancer drug that once targeted "breast cancer patients" now gets prescribed to women whose tumors carry a specific genetic fault, regardless of where the cancer started. The old approach, treating disease by what it looks like, dies fast. The new one treats disease by what it is made of at the molecular level.
Yet the shift creates sharp problems. In wealthy nations, genetic testing becomes standard care within five years. In poor ones, patients never see it. A Somali farmer with the same cancer as the Copenhagen woman will likely never get her chance at that tailored drug. Even in rich countries, questions of power loom large. Who owns the genetic data? Tech firms and hospital networks already fight over ownership rights, and governments have not caught up with rules. If a company owns your genome, can it sell insights to insurers? Can police demand it without a warrant?
The science works. Survival rates jump when doctors use genetic data to pick drugs and doses. Costs fall over time as the technology matures. Yet access remains unequal and will stay that way for decades. A patient in rural Missouri will get less benefit from this revolution than a wealthy resident of London. The gap between those who can afford personal genetic medicine and those who cannot will grow before it shrinks.
Medicine in 2030 will look nothing like medicine in 2020. Doctors will treat individuals, not disease categories. The revolution is real and the benefits are real. But so is the risk that it becomes a luxury good, available to some and forbidden to others.
In 54-jierige frou yn Kopenhaven kaam forig maitiid yn har kankerklinieken mei har persoanlike genoomrapport yn 'e hân. It tumor-DNA tochte in mutaasje dy't gefoelich wie foar in medikoadsynen dat se nea heard hie, ien dat standert behannelingsprotokollen nea soe hawwe foarskreaun. Sy begon mei it nije medikoadsynen, en seks moannen letter wiene har skan skjin. Dy saak werhellet him no tûsenen kearen per moanne, yn sikehûzen yn Jeropa, Aazje en Noard-Amearika. De kosten foar folslein genoomsequencing binne fallen fan 3 miljoen dollar yn 2003 nei minder as 200 dollar hjoed, en dy daling toant gjin teken fan stoppjen.
Sikehûzen wurkje hurd om genetyske laboratoria op te bouwen en spesjalisten oan te nimmen om de gegevens te lêzen. Fersekeringmaatskippijen werstele om te bepalen hokker testen sy dekke sille. Farmasiwtiske bedriuwen trainje har folsleine ferkeopteim opnij, om't medikadsynen net langer yn nette kategoryen passe. In kankerbetsjuttingsstoaf dy't eartiids "borstkanker pasyinten" behandele, wurdt no foarskreaun oan froulju waans tumoren in spesifike genetyske flater hawwe, nettsjinsteande dêr't de kanker begon. De âlde oanpak, it behannelen fan siken nei hoe't se derút sjogge, starveret gau. De nije behannelt siken nei wat it op molekulêr nivo is.
Toch makket de ferskowing skerpe problemen. Yn rike lannen wurdt genetysk testjen binnen fiif jier standertbehanneling. Yn arme lannen sjogge pasyinten it nea. In Somaliske boer mei deselde kanker as de Kopenhaven-frou sil wierskynlik nea har kâns krije op dat oanmakke medikoadsynen. Sels yn rike lannen rijse grutte fragen oer macht. Wa't eigner is fan de genetyske gegevens? Techbedriuwen en sikehûsnetwerken vekje al om eigendomsrjochten, en regeringen binne net op de hichte mei regels. As in bedriuw jo genoom besit, kin it ynsjogten oan fersekeraars ferkeapje? Kinne pleats it sûnder gerechtlik bevel easkje?
De wittenskip wurket. Oerlibbingspersintaazjes springe up as doktors genetyske gegevens brûke foar medikoadsynen en dosaasjes te kiezen. De kosten falle yn de tiid as de teknologie rijpt. Toch bliuwt de tagong ongelijk en sil dat dekaazjes lang sa bliuwe. In pasynt yn it plattelân fan Missouri sil minder profyt fan dy revolúsje hawwe as in wolsteande bewenner fan Londen. De kloft tusken dy't persoanlike genetyske medisinen betelje kinne en dy't dat net kinne, sil groeie eardat dy ôfnimt.
Medisinen yn 2030 sil heul oars derút sjogge as medisinen yn 2020. Doktors sille yndividuen behannele, net siektetaken. De revolúsje is echte en de foardielen binne echte. Mar jit sa is it risiko dat it in luxegoed wurdt, beskikber foar inkele en ferbean foar oaren.
Published December 18, 2025 · Frisian News · Ljouwert, Fryslân